T he promise of a cancer vaccination to fi ght tumors using the patient's own immune system is at the same time fascinating and challenging. Since cancer typically strikes at an older age, there is no evolutionary pressure on the immune system to develop successful anticancer effectors. This lack of evolutionary pressure to fi ght cancer is an apparent contrast to infectious diseases, for which a reasonable argument can be made that the immune system has evolved to fi ght pathogens. These assumptions might explain the relative success of vaccine development in the area of infectious diseases, and the long history of failed attempts in cancer vaccination.
And yet there is overwhelming evidence from laboratory studies that specifi c effectors of the immune system are able to recognize and destroy cancer cells. Soluble effectors of the immune system, such as antibodies, are now reliable weapons in the fi ght against lymphomas [1] . The graftversus-leukemia effect (immunological rejection of leukemia cells following bone marrow transplantation) strongly indicates the power of the immune system to control certain tumors [2] . Thus, the immune system, even though primarily evolved to fi ght pathogens, clearly has the means to fi ght cancer.
Challenges of Cancer Vaccination
What are the prerequisites for a successful anticancer immune response? Before destruction of a tumor is achieved by the host immune system, a simplifi ed four-step scenario has to take place: (1) activation and expansion of tumor-specifi c effector cells, (2) migration of effector cells to the tumor site, (3) effector-cell recognition of tumor cells, and (4) effector-cell destruction of tumor cells. In addition, a quantitative balance between the number of tumor cells and effector cells needed to destroy the tumor has to be taken into account. All these steps need to be investigated and controlled for successful cancer vaccination.
Cytotoxic T cells are among the best-investigated effector cells of the immune system. There is strong evidence that the presence of intratumoral T cells correlates with improved clinical outcome in certain human cancers during the natural immune response against tumors [3] . Dendritic cells are among the most powerful activators of tumor-specifi c helper cells and cytotoxic T cells [4] . Expansion of human tumor antigenspecifi c helper cells and cytotoxic T cells in peripheral blood has been demonstrated using antigen-pulsed dendritic cells as well as intracutaneous peptide immunization in the presence or absence of adjuvant [5] [6] [7] .
There is, however, limited insight into the magnitude, breadth, and molecular nature of the induced immune responses. There are also currently no means to discriminate between protective and nonprotective (curative and noncurative) T cell responses. In fact, we are not certain about the frequency of tumor antigenspecifi c T cells that is necessary for tumor destruction. While viral protection models suggest that a high frequency (number) of vaccineinduced specifi c effectors is necessary, alternative hypotheses favor the generation of low-frequency vaccineinduced responses, which might in turn affect pre-existing antitumor-specifi c T cells [8] . Therefore, new developments in the area of monitoring and understanding the tumor-specifi c immune response, in combination with small innovative pilot vaccine trials, are needed.
Monitoring of the Cancer Immune Response
There are many ways to assess a cancerspecifi c immune response, including monitoring (1) direct cytotoxicity of effectors, as measured by chromium release assays (see Glossary), (2) cytokine release from effector cells, as assessed by fl ow cytometry or enzyme-linked immunosorbent assay techniques, (3) T cell receptor (TCR) specifi cities, as assessed by MHC-peptide multimers, (4) clonal composition of the T cell response via CDR (complementarity-determining region) 3 spectratyping, and (5) T cell degranulation via cell surface exposure of cluster designation (CD)107 [9] [10] [11] .
Many of these techniques are useful, but fail to fully assess the functional complexity of an anticancer T cell response in a comprehensive manner. Analyzing T cell specifi cities using MHC-peptide multimers has revolutionized the fi eld of cancer vaccination, but does not provide insights into T cell function. Detection of interferon-γ production by tumor-specifi c T cells gives some functional insights, but lacks information about TCR specifi cities and does not cover the broad spectrum of potential effector cytokines. Indeed, studies of chronic viral infection models suggest the relevance of multiple cytokines such as interferon γ, interleukin 2, and tumor necrosis factor α for effector T cell fi tness [12] .
A New Study of a Novel Immunomonitoring Tool
A new study by Chen et al. in the current issue of PLoS Medicine provides a novel approach to these scientifi c issues, and increases our insight into the vaccineinduced anticancer immune response using a novel immunomonitoring tool [13] . The tool combines analysis of TCR specifi cities with detection of cytokine production in a multiparametric microarray platform. The authors array HLA-A2-immunoglobulin dimers loaded with the peptide of interest with cytokine-capturing antibodies on three-dimensional substrates composed of microscope slides coated with a polyacrylamide gel. This allows the comprehensive analysis of multiple T cell specifi cities and functional outcomes. Similar platforms were recently used to investigate antigenspecifi c T cell clones [14] . The current study, however, provides the fi rst comprehensive analysis of vaccineinduced antitumor immune responses in patients with cancer.
One of the most striking fi ndings is the marked variation of responses toward well-defi ned peptide vaccines. Variation of the response was seen both at the level of a single patient and, independently, at the level of the specifi c antigen. Thus, no patient or antigen-specifi c functional response pattern was observed. Even though the current study does not allow defi nitive conclusions about a link between specifi c cytokine secretion profi les and clinical outcomes, it appears as if both interferon γ and tumor necrosis factor α were relevant for tumor clearance, as indicated by prolonged recurrence-free periods in patients with such a cytokine profi le.
Implications of the Study
The study raises several questions. Are cytokine signatures present in certain subpopulations of effector T cells, especially those successful in tumor rejection? Are cytokine signatures predictive of the clinical outcome? It will be interesting to test T cell subpopulations, especially those derived from secondary lymphoid tissues and the tumor site. Are there cytokine signatures in response to pathogens or pathogen-specifi c vaccines, and how do these signatures differ from those induced by cancer vaccines? Antibody responses might be detected by protein microarrays [15] . Are there ways to array and functionally analyze other components of the immune system such as NKT cells, NK cells, or granulocytes?
Taken together, the current study establishes the fundamentals for future application of high-throughput multiparametric platforms that simultaneously capture antigen-specifi c T cells and detect secreted products in the analysis of tumor and, potentially, pathogen-specifi c immune responses.
